Cyclacel Pharmaceuticals Statistics Share Statistics Cyclacel Pharmaceuticals has 1.58M
shares outstanding. The number of shares has increased by 1.02%
in one year.
Shares Outstanding 1.58M Shares Change (YoY) 1.02% Shares Change (QoQ) 1% Owned by Institutions (%) 0.23% Shares Floating 1.45M Failed to Deliver (FTD) Shares 12,721 FTD / Avg. Volume 0.68%
Short Selling Information The latest short interest is 123.11K, so 7.77% of the outstanding
shares have been sold short.
Short Interest 123.11K Short % of Shares Out 7.77% Short % of Float 15.93% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -66.85 and the forward
PE ratio is -0.03.
Cyclacel Pharmaceuticals's PEG ratio is
0.7.
PE Ratio -66.85 Forward PE -0.03 PS Ratio 17429.8 Forward PS 142.8 PB Ratio -344.75 P/FCF Ratio -93.8 PEG Ratio 0.7
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Cyclacel Pharmaceuticals.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 0.59,
with a Debt / Equity ratio of 0.
Current Ratio 0.59 Quick Ratio 0.59 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $3.58K Profits Per Employee $-934.33K Employee Count 12 Asset Turnover 0.01 Inventory Turnover n/a
Taxes Income Tax -782K Effective Tax Rate 6.52%
Stock Price Statistics The stock price has increased by -97.26% in the
last 52 weeks. The beta is 0.09, so Cyclacel Pharmaceuticals's
price volatility has been higher than the market average.
Beta 0.09 52-Week Price Change -97.26% 50-Day Moving Average 9.24 200-Day Moving Average 66.07 Relative Strength Index (RSI) 45.36 Average Volume (20 Days) 1,879,210
Income Statement In the last 12 months, Cyclacel Pharmaceuticals had revenue of 43K
and earned -11.21M
in profits. Earnings per share was -1.36.
Revenue 43K Gross Profit 37K Operating Income -12M Net Income -11.21M EBITDA -12M EBIT -12M Earnings Per Share (EPS) -1.36
Full Income Statement Balance Sheet The company has 3.14M in cash and 0 in
debt, giving a net cash position of 3.14M.
Cash & Cash Equivalents 3.14M Total Debt n/a Net Cash n/a Retained Earnings -439.49M Total Assets 3.73M Working Capital 3.05M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -7.99M
and capital expenditures 0, giving a free cash flow of -7.99M.
Operating Cash Flow -7.99M Capital Expenditures n/a Free Cash Flow -7.99M FCF Per Share -0.96
Full Cash Flow Statement Margins Gross margin is 86.05%, with operating and profit margins of -27916.28% and -26074.42%.
Gross Margin 86.05% Operating Margin -27916.28% Pretax Margin -27893.02% Profit Margin -26074.42% EBITDA Margin -27902.33% EBIT Margin -27916.28% FCF Margin -18581.4%
Dividends & Yields CYCC does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for CYCC is $11,
which is 22% higher than the current price. The consensus rating is "Buy".
Price Target $11 Price Target Difference 22% Analyst Consensus Buy Analyst Count 1
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jul 7, 2025. It was a
backward
split with a ratio of 1:15.
Last Split Date Jul 7, 2025 Split Type backward Split Ratio 1:15
Scores Altman Z-Score -163.01 Piotroski F-Score 3
